In addition, our data endorse the interest of analgesic drugs inhibiting TRPA1 activity for the treatment or prevention of migraine and pain syndromes characterized by enhanced mechanosensitivity in males and females2,43,71, although careful modulation may be desirable since TRPA1 shows neuroprotective effects as a hypoxia sensor that drives vasodilation and reduces ischemic damage72. The gene discussed is TRPA1; the disease is migraine disorder.